Jazz Pharmaceuticals (NASDAQ:JAZZ) Releases FY 2025 Earnings Guidance

Jazz Pharmaceuticals (NASDAQ:JAZZ) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 7.650-8.450 for the period, compared to the consensus estimate of 3.830. The company issued revenue guidance of $4.2 billion-$4.3 billion, compared to the consensus revenue estimate of $4.2 billion.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on JAZZ. JPMorgan Chase & Co. lowered their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a report on Monday, October 27th. Weiss Ratings restated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, October 8th. Wells Fargo & Company set a $170.00 price objective on Jazz Pharmaceuticals in a research note on Wednesday, October 22nd. Needham & Company LLC reissued a “buy” rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Finally, The Goldman Sachs Group raised their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a research report on Friday, August 29th. Fourteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $179.60.

Jazz Pharmaceuticals Trading Down 2.3%

Shares of NASDAQ JAZZ traded down $3.17 during trading hours on Thursday, hitting $134.05. The company’s stock had a trading volume of 1,136,175 shares, compared to its average volume of 892,537. The business has a 50-day simple moving average of $132.98 and a 200-day simple moving average of $118.98. The stock has a market cap of $8.13 billion, a price-to-earnings ratio of -19.92, a P/E/G ratio of 8.49 and a beta of 0.29. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals has a 12 month low of $95.49 and a 12 month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share for the quarter, topping analysts’ consensus estimates of $5.87 by $2.26. The firm had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period last year, the company earned $6.54 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, analysts anticipate that Jazz Pharmaceuticals will post 16.96 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 3,500 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $140.00, for a total transaction of $490,000.00. Following the sale, the director owned 408,826 shares of the company’s stock, valued at approximately $57,235,640. The trade was a 0.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 11,500 shares of company stock valued at $1,525,280. Company insiders own 4.30% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Several large investors have recently bought and sold shares of JAZZ. Ameriprise Financial Inc. raised its position in shares of Jazz Pharmaceuticals by 11.4% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after acquiring an additional 191,637 shares in the last quarter. Vestal Point Capital LP bought a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $127,344,000. Bank of America Corp DE grew its stake in Jazz Pharmaceuticals by 8.7% in the second quarter. Bank of America Corp DE now owns 1,052,470 shares of the specialty pharmaceutical company’s stock worth $111,688,000 after purchasing an additional 83,937 shares during the period. AQR Capital Management LLC raised its holdings in Jazz Pharmaceuticals by 62.1% in the second quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock worth $84,341,000 after purchasing an additional 304,463 shares in the last quarter. Finally, Sofinnova Investments Inc. lifted its position in Jazz Pharmaceuticals by 36.1% during the second quarter. Sofinnova Investments Inc. now owns 694,096 shares of the specialty pharmaceutical company’s stock valued at $73,657,000 after buying an additional 184,046 shares during the period. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.